Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New use of gene reconstituted urokin as origin

A technology of pro-urokinase and gene recombination, which can be applied to medical preparations containing active ingredients, drug combinations, blood diseases, etc., and can solve the problems that there is no Pro-uk

Inactive Publication Date: 2005-08-10
TASLY BIOPHARMACEUTICALS CO LTD
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Traditional treatment methods for acute retinal artery infarction (CRAO) often use anterior chamber puncture, visual massage, carbonic anhydrase inhibitors, etc., but they can hardly change the spontaneous course of the disease
At present, there are literature reports on the use of thrombolytic agents in the treatment of CRAO at home and abroad, but there is no report on Pro-uk for the treatment of CRAO

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New use of gene reconstituted urokin as origin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0082] Cloning of Prourokinase Gene and Construction of Expression Vector

[0083] (1) Construction and cloning of the full-length cDNA gene of human prourokinase: Detroit 562 cells were induced with myristyl ester (PMA), and the total RNA of the cells was extracted by the acid thiocyanate-phenol-chloroform method, and Oligo(dT)-fiber Separation of poly(A) by plain column chromatography + ) RNA, the cDNA library of Detroit 562 cells was constructed by reverse transcription and dG·dC tailing recombination technology, and the positive clones containing the gene fragment encoding urokinase were obtained by screening. Using artificially synthesized oligonucleotide fragments and DNA recombination technology, the full-length cDNA gene of human prourokinase was constructed and cloned into the pUC19 plasmid, and the PMM-UK recombinant plasmid was obtained, which was confirmed by sequencing. The 5' end of the gene contains Hind III and EcoR1 single restriction sites, and the 3' end co...

Embodiment 2

[0088] Transfection and screening of highly expressed CHO engineered cells

[0089] Transfect 20-40 μg of pMTSV-du plasmid DNA into CHO-dhfr- cells by calcium phosphate co-precipitation method, first screen with HAT selection medium, and then replace with 1-3×10 -8 The selection medium of M MTX is double-selected by dhfr and MTX, and the positively transformed cells expressing pro-urokinase activity are subjected to multiple subcloning and MTX pressurized amplification of the gene, induced by zinc ions, and finally screened to highly express urokinase original cell line.

Embodiment 3

[0091] Cultivation and scale-up of CHO engineered cells

[0092] CHO engineered cells consist of square flask (monolayer adherent culture)-spinner bottle (monolayer adherent culture)-stirred flask (porous microcarrier culture)-5L Celligen reactor (porous microcarrier culture)-30L Biostat UC reactor ( Porous microcarrier culture) step by step scale-up culture. Since the cells can be automatically transferred between the carrier full of cells and the empty carrier, when each stage of scale-up culture is carried out, an appropriate amount of medium and treated porous microcarriers are pre-added in a larger-scale reactor, and the porous microcarriers full of cells The microcarriers are directly approached to the next-stage reactor through the pipeline. The control pH is 7.0±0.5, DO is 7%-40%, temperature is 37.0±0.1°C, stirring speed is 70r / min-90r / min. The concentration of porous microcarrier is 2g / L-g / L culture medium. The continuous culture method of batch type medium exchang...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An application of gene-recombinant prourokinase in preparing medicines for treating acute myocardial infarction, cerebral infarction, pulmonary embolism, phlebothrombosis of leg, etc is disclosed.

Description

technical field [0001] The present invention relates to the use of gene recombinant urokinase, in particular to the application of gene recombinant urokinase in the field of pharmacy. Background technique [0002] Thrombotic diseases, including acute myocardial infarction (AMI), cerebral infarction, pulmonary embolism, deep vein thrombosis of lower extremities, retinal artery and vein thrombosis, etc., are a class of diseases that seriously endanger the lives and health of people all over the world. In the United States, 35% of deaths among men aged 35 to 50 are caused by AMI. Among the top ten fatal diseases in the world, coronary heart disease (angina pectoris, myocardial infarction and sudden cardiac death) ranks first, with 7.2 million deaths per year, and cerebrovascular disease ranks third, with an annual death toll of 4.6 million. Cardiovascular and cerebrovascular diseases are still on the rise. About 13 million people in the world suffer f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/49
CPCA61K38/49A61P7/02A61P11/00
Inventor 姜燕
Owner TASLY BIOPHARMACEUTICALS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com